Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

5articles mentioning drugs

25drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: GDF-15 ×

GDF-15

This drug is selected. Its supporting articles are shown below.

Articles mentioning GDF-15

5 articles · page 1 of 1

864 Delineating the role of growth differentiation Factor 15 (GDF-15) in advanced bladder and upper tract urinary cancers (BC): university of Washington rapid autopsy program (UW-RAP) cohort

jitc · abstract · 2025-11-04 · 17 matching annotations

93.5%

…nts who received more lines of systemic therapy (p=0.08). Serum GDF-15 levels correlated with higher IFN-γ (β = 0.49, p = 0.011), IL-1…

P.082 Serum proteins reflecting vascular processes associate with interstitial lung disease development in patients with systemic sclerosis

jsrd · abstract · 2026-06-05 · 3 matching annotations

94.2%

CCL15 GDF-15 U-PAR TNFSF13B Gal-3 PSP-D FABP4 TNF-R2 TNFRSF14

…994, p=0.006), GDF-15 (1.194, p<0.001), U-PAR (0.630, p=0.008), CCL15 (0.938, p=0.015), PSP-D (1.106, p<0.001) and TNFSF13B (0.944, p…

519 GDFATHER-01 trial longterm follow-up: GDF-15 neutralization combined with nivolumab can enable deep, longterm remission in heavily pretreated, anti-PD1/-L1 relapsed/refractory major solid tumor types

jitc · abstract · 2025-11-04 · 3 matching annotations

84.9%

visugromab nivolumab GDF-15 V HCC nsq-NSCLC NSCLC

…L1 treatment and received the experimental anti-GDF-15 antibody visugromab and nivolumab…

P.241 Serum biomarker components align with lung and cardiac phenotypes in systemic sclerosis through principal component analyses (PCA

jsrd · abstract · 2026-06-05 · 1 matching annotations

78.7%

YKL-40 GDF-15 S100A8/A9 SSc ischemic heart disease interstitial lung disease ILD

…cal significance. Finally, PC4, marked by positive contribution YKL-40 and TIMP-1, and negative from MMP-9, was associated with perica…

809 Phenotypic evaluation of natural killer cells in hepatocellular carcinoma for CAR-NK cell development

jitc · abstract · 2025-11-04 · 1 matching annotations

75.3%

IL-15 IL-2 IL-7 GDF-15 Hepatocellular carcinoma (HCC)hepatocellular carcinoma HCC Chimeric antigen receptor natural killer cell (CAR-NK) therapy

… vitro with different doses of cytokines, including IL-2, IL-7, IL-15. IL-2 stimulated human NK cells were co-cultured with human HCC…